期刊文献+

LC-MS/MS法测定人血浆中伊伐布雷定浓度及药动学 被引量:3

Determination of Ivabradine in Human Plasma by LC-MS/MS and Study of Pharmacokinetics
原文传递
导出
摘要 目的:建立人血浆中伊伐布雷定的液相色谱-质谱-质谱联用测定方法,研究健康人体药代动力学。方法:以地西泮为内标物,采用液相色谱-质谱-质谱联用法,电喷雾电离源选择性正离子峰检测。测30名健康志愿者单剂量口服盐酸伊伐布雷定片的体内血药浓度,获得药动学参数。结果:伊伐布雷定在0.101-101 ng·mL-1浓度范围内呈良好的线性关系(r=0.998),最低检测浓度为0.101 ng·mL-1。高、中、低浓度的方法提取回收率分别为93.2%、86.6%、87.5%,日内、日间精密度RSD均小于15%。结论:LC-MS/MS方法灵敏度高,专属性强,准确,简便,适用于盐酸伊伐布雷定片的人体药代动力学研究。 Objective: To determine ivabradine in human plasma by a LC/MS/MS method,and to investigate its pharmacokinetics.Methods: Ivabradine concentrations in plasma were determined by LC-MS/MS.The test and reference formulations of ivabradine were given to 30 healthy male volunteers.Results: The linear range for rosuvastatin was 0.101-101 ng·mL-1(r = 0.998).The quantitation limit for rosuvastatin was 0.101 ng·mL-1.The draw recovery rates were 93.2 %,86.6 % and 87.5 %,and RSD for intra-day and inter-day was both less than 15 %.Conclusion: LC-MS/MS method is sensitive,accurate and simple,and suitable for the study on pharmacokinetic of ivabradine in human.
出处 《现代生物医学进展》 CAS 2011年第14期2605-2608,共4页 Progress in Modern Biomedicine
基金 国家科技重大专项课题(2008ZX09312-024)
关键词 伊伐布雷定 药代动力学 液相色谱-质谱-质谱 Ivabradine Pharmacokinetics LC-MS/MS
  • 相关文献

参考文献20

  • 1Tardif JC. Clinical efficacy of i vabradine [J]. Heart Drug, 2005, 5 (1): 25-28.
  • 2DiFrancesco D. Ivabradine - a first-in-its-class treatment for lowering heart rate[J]. Cardiovasc J Afr, 2009, 20(1):96.
  • 3Prasad UK, Gray D, Purcell H. Review of the If selective channel inhibitor ivabradine in the treatment of chronic stable angina [J]. Adv Ther, 2009, 26(2): 127-137.
  • 4Bucchi A, Baruscotti M, DiFrancesco D. Current-dependent block of rabbit sino-atrial node If channel by ivabradine [J]. J Gen Physiol, 2002,120(1):1-13.
  • 5Bois P, Bescond J, Renaudon B, et al. Mode of action of bradycardic agent S 16257, on ionic current in sinoatrial node cells [J]. Br J Pharmacol, 1996,118:1051-1057.
  • 6Wickenden AD, Maher MP, Chaplan SR. HCN pacemaker channels and pain: a drug discovery perspective [J]. Curr Pharm Des, 2009,15 (18):2149-2168.
  • 7Joannides R. Comparative effects of inabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemo- dynamics at rest and during exercise [J]. Br J Clin Pharma col, 2006,61:127-137.
  • 8Baruscotti M, Barbuti A, Bucchi A. The cardiac pacemaker current[J]. J Mol Cell Cardiol, 2010, 48(1):55-64.
  • 9Pathak A, Berdeaux A, Mulder P, et al. Ivabradine in coronary heart disease: experimental and clinical pharmacology [J]. Therapie, 2010, 65(5):483-489.
  • 10Manz M, Reute M, Lauck G, et al. A single intravenous dose of ivabradine, a novel If inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction [J]. Cardiology, 2003,100:149-155.

同被引文献55

  • 1Brown H, Difrancesco D. Voltage-clamp investigations of membrane currents underlying pace-maker activity in rabbit sino-atrial node[J]. J Physiol, 1980, 308(8): 331-351.
  • 2Manz M, Reuter M, Lauck G; et al. A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction[J]. Cardiology, 2003, 100(2): 149-155.
  • 3Colin P, Ghaleh B, Hittinger L, et al. Differential effects of heart rate reduction and beta-blockade on left ventricular relaxation during exercise[J]. Am J Physiol Heart Cite Physiol, 2002, 282(7): H672-679.
  • 4Kolloch R, Legler UF, Champion A, et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the international verapamil-SR/trandolapril study (INVEST)[J]. Eur Heart J, 2008, 29(2): 1327-1334.
  • 5Siasos G, Tousoulis D, Athanasiou D, et al. Novel risk factors related to stable angina[J]. Curr Pharm Des, 2013, 19(2): 1550-1561.
  • 6Arrebola-Moreno A, Dungu J, Kaski JC. Treatment strategies for chronic stable angina[J]. Expert Opin Pharmacother, 2011, 12(3): 2833-2844.
  • 7Riccioni G Ivabradine: an intelligent drug for the treatment of ischemic heart disease[J]. Molecules, 2012, 17(2): 13592-13604.
  • 8Doesch AO, Mueller S, Erbel C, et al. Heart rate reduction for 36 months with ivabradine reduces left ventricular mass in cardiac allograil recipients: a long-term follow-up study[J]. Drag Des Devel Ther, 2013, 7(1): 1323-1328.
  • 9Villano A, Di FA, Nerla R, et al. Effects of ivabradine and ranolazine in patients with microvascular angina pectoris[J]. Am J Cardiol, 2013, 112(2): 8-13.
  • 10Skalidis EI, Hamilos MI, Chlouverakis G, et al. Ivabradine improves coronary flow reserve in patients with stable coronary artery disease [J]. Atherosclcrosis, 2011, 215 (2): 160-165.

引证文献3

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部